art-header-clip
ExploreTrial

                                                  btnGotoERCF

EXPLORE COMPLETED!!!!

304 patients enrolled!

Endpoints

Primary Endpoints

Measured by cardiovascular magnetic resonance imaging at 4 months:

  • Left ventricular ejection fraction
  • Left ventricular end-diastolic volume

Secondary Endpoints

Safety Endpoints

  • Major Adverse Cardiac Events, defined as cardiac death, myocardial infarction or CABG at 30 days, 4 months, and 1, 2, 3, 4, and 5 years.
  • Stent thrombosis, classified as definite, probable or possible

Other Secondary Endpoints

Measured by cardiac magnetic resonance imaging at 4 months:

  • Left ventricular end systolic volume
  • Left ventricular segmental wall thickening
  • Left ventricular mass√ćnfarct size 
  • Infarct size
  • N-terminal-proBrain Natriuretic Peptide (at 4 months and 1 year, relative to baseline)
  • Heart rate adjusted QT duration measured by resting electrocardiogrpahy (at 4 months and 1 year, relative to baseline)
  • Quantitative Coronary Angiography of the treated chronic total occlusions: in-stent and in-segment late luminal loss at 12 months 
  • In-stent and in-segment minimal luminal diameter
  • In-stent and in-segment binary restenosis rate
  • Repeat hospitalization for cardiac causes at 30 days, 4 months, and 1, 2, 3, 4, and 5 years
  • Presence of clinically overt heart failure at 30 days, 4 months, and 1, 2, 3, 4, and 5 years
  • Implantation of implantable cardioverter-defibrillator devices
  • Functional Class: NYHA classification at 30 days, 4 months, and 1, 2, 3, 4, and 5 years